Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb and Five Prime partner for antibody program
The program also includes FPA008 which is in its initial development stage for immunology as well as oncology indications. Under the terms of the agreement, Five Prime will
The program also includes FPA008 which is in its initial development stage for immunology as well as oncology indications. Under the terms of the agreement, Five Prime will
Resunab is a novel oral drug designed to target the resolution of chronic inflammation and debilitating fibrosis associated with disease progression in CF across all cystic fibrosis transmembrane
The Novartis portfolio is being offered to the Kenyan government, non-governmental organizations and other public-sector healthcare providers for USD 1 per treatment, per month. "Novartis and Kenya have
As part of the deal, Johnson & Johnson Innovation – JJDC will provide upfront payment and equity investment for engine, in addition to R&D funding. The deal will
FDA has provided recommendations specific to the moderate to severe chronic plaque psoriasis sNDA. Pfizer said that it will work with FDA to determine an appropriate path forward
By collaborating with University Health Network, the biotechnology company Novera will discover and develop novel therapeutic compounds identified through OICR’s drug discovery program. The company will coordinate the
Under the deal, ImaginAb will be responsible for conducting preclinical research using its immune imaging agent, IAB22M2C (a clinical anti-human CD8 probe), to detect T-cell trafficking, redirection and
The approval comes through Health Canada, the regulating health-care agency of Canada. PharmaRoth CEO Luis Lopez said: "We are very excited that our product is expanding into the
The transaction will enhance Hi-Tech’s leading Sports Nutrition arsenal and expand its distribution through iForce’s strong distribution network. Hi-Tech chairman, president and CEO Jared Wheat said: "The combination
CINRYZE received the designation for investigation in the treatment of antibody mediated rejection (AMR) in patients receiving kidney transplants. The injectable prescription medicine is used to help prevent